Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus bevacizumab versus osimertinib alone in stable disease EGFR-mutant non-squamous non-small cell lung cancer
ChiCTR1800019543Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of osimertinib and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Progression-free survival. Started Nov 2018; status: recruiting.
02
Drugs
osimertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019543.